# BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.

> **NCT00326963** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 142 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Background ARVs
- **DRUG:** PI
- **DRUG:** enfuvirtide [Fuzeon]

## Key facts

- **NCT ID:** NCT00326963
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2007-04
- **Final completion:** 2007-05
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2016-08-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00326963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00326963, "BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00326963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*